CYC 101Alternative Names: CYC101
Latest Information Update: 04 Nov 2002
At a glance
- Originator CNRS; Cyclacel; University of Dundee
- Mechanism of Action Cyclin-dependent kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Aug 2001 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
- 17 Feb 1998 Preclinical development for Cancer in United Kingdom (Unknown route)